MDR1-EXPRESSING CD4+ T CELLS WITH TH1.17 FEATURES RESIST TO NEOADJUVANT CHEMOTHERAPY AND ARE ASSOCIATED WITH BREAST CANCER CLINICAL RESPONSE.
Di Roio A, Hubert M, Besson L, Bossennec M, Rodriguez C, Grinberg-Bleyer Y, Lalle G, Moudombi L, Schneider R, Degletagne C, Treilleux I, Campbell DJ, Metzger S, Duhen T, Trédan O, Caux C, Ménétrier-Caux C.
Di Roio A, et al. Among authors: metzger s.
J Immunother Cancer. 2023 Nov;11(11):e007733. doi: 10.1136/jitc-2023-007733.
J Immunother Cancer. 2023.
PMID: 37940345
Free PMC article.